LOG Standards Daily Briefing: Regulatory Tightening and AI Safety Imperatives in Healthcare

The integration of artificial intelligence into healthcare has entered a highly complex phase characterized by aggressive deployment, evolving regulatory mandates, and heightened safety evaluations. As health systems transition AI from small-scale pilots to embedded clinical infrastructure—exemplified by joint transformation platforms like the one launched by KT and Seoul National University Hospital—the need for robust governance has never been more acute. Stakeholders across the globe are grappling with how to balance the promise of workflow efficiency and clinical decision support against profound risks to patient safety, data equity, and ethical standards. Regulatory frameworks are solidifying across jurisdictions, setting strict boundaries for software classification and deployment. In the United States, the FDA’s finalized Clinical Decision Support Software guidance provides a critical four-part test to determine whether an AI tool functions as a regulated medical device. This is complemented by new state-level disclosure requirements in California and Texas, as well as complex policy shifts such as the HHS proposed HTI-5 rule, which critics warn could widen governance gaps by rolling back model-card disclosures and transparency mandates. Internationally, the EU AI Act is aligning with medical device regulations (MDR/IVDR), establishing that systems used for diagnosis, triage, or clinical recommendations are classified as high-risk, carrying stringent compliance obligations and significant penalties. In the realm of clinical AI and mental health, recent literature underscores an alarming divergence between public adoption and clinical-grade evidence. A surge in young people utilizing AI chatbots for anxiety and depression support—highlighted by recent survey data and tragic case studies—has exposed severe vulnerabilities. Systematic reviews published in the medical literature reveal that while chatbots can yield short-term symptom reductions, studies are plagued by small sample sizes, weak controls, and heterogeneous designs. Furthermore, advanced reasoning models such as ChatGPT and DeepSeek continue to reproduce significant racial (up to 85%) and gender (up to 61%) biases, risking disparate care delivery when deployed in clinical settings. Moreover, ethical evaluations of generative models acting as therapeutic agents demonstrate frequent violations of core mental health standards, including boundaries, informed consent, and acute crisis handling. General-purpose models frequently fail to recognize suicidal ideation safely, creating dangerous parasocial dependencies. These findings reinforce warnings from clinical bodies that large language models cannot replace licensed human care without strict guardrails, prospective validation, and standardized oversight. Conversely, enterprise-grade administrative and clinical documentation tools are expanding rapidly. Innovations like Abridge's broad deployment across 300 health systems—serving over 250 million patients—demonstrate how context-aware AI can safely assist with pre-visit summaries, medical literature linkages, and referral drafting when integrated directly into existing digital workflows. Similarly, the introduction of medicines management decision support tools at trusts like Calderdale and Huddersfield illustrates the value of targeted, workflow-embedded safety checks. From the LOG Standards perspective, these developments validate our core mission: the establishment of rigorous, independent accreditation and operational governance for clinical AI. As agentic AI and autonomous clinical assistants face stricter transparency rules under the EU AI Act and clinician demands for prospective validation, health systems must move beyond passive adoption. Stakeholders must implement comprehensive bias management, continuous post-market monitoring, and strict adherence to regulatory standards to ensure that clinical AI systems remain safe, equitable, and accountable at scale.